Home | Publications | Country | Middle East place holder
place holder place holder

Middle East


Major Pharmaceutical Markets of the Middle East

An overview of Egypt, Israel, Jordan, Lebanon, Saudi Arabia & UAE

Publication Date   April 2006
Publisher   URCH Publishing
Product Type   Report
Pages   100
ISBN Number   0954698150
Product Code   URC149
Ask a question about this product?

Price £799.00

approximately: $1,411 | €1,013

Summary


A a comprehensive report providing extensive coverage of one of the strongest emerging markets. Through quality analysis and forecasts, this unique report will allow you to identify market trends and growth potential opportunities.

The report provides the necessary background information for a firm to operate in the region.

Chapter summaries:

Chapter 1: covers the main characteristics of the Middle Eastern market through a Political, Economic, Social and Technological (PEST) analysis, plus insight into the tax environment and Free-Trade Agreements in place or being negotiated.

Chapter 2: reports on the Intellectual Property Rights environment of each of the countries covered.

Chapter 3: provides a overview of the regional pharmaceutical market, and includes data on consumption, production, imports, exports, as well as market forecasts.

The other chapters are in-depth per-country market studies.

Country coverage
Egypt, the largest pharmaceutical market of the region
Israel, home to the world's largest generic drug company
Jordan, the leading Arab pharmaceutical exporter
Lebanon, an almost exclusive import market
Saudi Arabia, the largest market of the Gulf
The United Arab Emirates, among the highest-priced markets in the region

Five key findings

The Middle East market has achieved impressive growth to reach $8bn worth in 2005. The regional pharmaceutical Combined Annual Growth Rate (CAGR) between 1999-2003 was second only to Southeast Asia and China.
The Middle East is a high-import market. Israel, Jordan, Saudi Arabia and Lebanon import respectively 60%, 70%, 80% and 94% of their pharmaceutical needs.
Local manufacturing capabilities are constrained to generics.
A high acceptance of Western medicines is present
Generics have a low market penetration as most countries apart from Egypt are considered brand-name countries.

What you can learn from this report

Which multinationals have invested in the Middle East
Who are the leading local pharmaceutical manufacturers and distributors
What are the trends in the pharmaceutical market and import and export sizes
How Intellectual Property Rights and patents are the most conflictual regional issue
Which countries have implemented health insurance and the likely impact on growth
What type of demand and supplyside cost controls are in place

Reasons to purchase the report

Five-year projected sales figure to enable proprietary forecasting
Detailed Political, Economic, Social and Technological (PEST) analysis providing thorough regional and country background
Extensive list of local contacts to facilitate finding a potential business partner
Thorough review of country pharmaceutical markets using latest available data
Researched by a native speaker using primary and secondary data

Content


Chapter 1: Characteristics of the Middle Eastern Pharmaceutical Market

Political, economic, social and technological (PEST) analysis
Political factors
Economic factors
Social factors
Technological factors
Free trade agreements
Euro-Mediterranean Free Trade Area (EU-MEFTA)
US-MEFTA (Middle East Free Trade Agreements)
Gulf Cooperation Council (GCC)
Taxation
Egypt
Israel
Jordan
Lebanon
Saudi Arabia
United Arab Emirates

Chapter 2: Intellectual Property Rights

Trade-related Aspects of Intellectual Property Rights (TRIPS)
Egypt
Israel
Jordan
Lebanon
Saudi Arabia
United Arab Emirates

Chapter 3: Overview of the Middle Eastern Pharmaceutical Market

Healthcare overview
Pharmaceutical consumption
Domestic production
Imports
Market forecast

Chapter 4: Egypt

The healthcare structure
The pharmaceutical market
Market figures
Drug pricing and reimbursement
Distribution
Cost controls
Public tenders
Patient co-payment
Generic substitution
Leading companies

Chapter 5: Israel

The healthcare structure
The pharmaceutical market
Market figures
Drug pricing and reimbursement
Distribution
Cost controls
Prescribing limitations
Generic substitution
Patient co-payment
Leading companies

Chapter 6: Jordan

The healthcare structure
The pharmaceutical market
Market figures
Point of interest: medical tourism
Drug pricing and reimbursement
Distributio
Cost controls
Co-payment
Public-sector procurement
Leading companies

Chapter 7: Lebanon

The healthcare structure
Point of interest: fraud
The pharmaceutical market
Market figures
Drug pricing and reimbursement
Distribution
Cost controls
Public procurement
National Drugs Office
Patient co-payment
Leading companies

Chapter 8: Saudi Arabia

The healthcare structure
Pharmaceutical market
Market figures
Drug pricing and reimbursement
Distribution
Cost controls
Private health insurance provision
'Dollarisation'
Gulf Cooperation Council bulk buying
Leading companies

Chapter 9: United Arab Emirates

The healthcare structure
Pharmaceutical market
Market figures
Drug pricing and reimbursement
Distribution
Cost controls
Bulk buying
Co-payment
Leading companies

Appendix

Abbreviations
Useful contacts
Egypt
Israel
Jordan
Lebanon
Saudi Arabia
United Arab Emirates
Selected bibliography

List of Figures

Figure 3.1 Projected market sizes for Egypt, Saudi Arabia and Israel
Figure 3.2 Projected market sizes for the UAE, Lebanon and Jordan
Figure 4.1 Exchange rate fluctuations (Egyptian pounds to the US dollar), 1997-2005
Figure 5.1 Drug purchasers by share, 2001
Figure 6.1 Jordan's sources of healthcare funds
Figure 6.2 Jordan's national health expenditure, by healthcare provider
Figure 7.1 Institutional framework of Lebanon's pharmaceutical sector
Figure 9.1 Purchasers of pharmaceuticals in the public sector

List of Tables

Table 1.1 Regional PEST factors affecting the pharmaceutical industry in the Middle East
Table 2.1 Estimates of intellectual property losses inflicted on PhRMA members, 2004
Table 3.1 Health indicators, 2003
Table 3.2 Pharmaceutical market sizes in the Middle East, 2003
Table 3.3 Annual per capita drug consumption figures in the Middle East, 2001
Table 3.4 Largest local pharmaceutical manufacturers in the Middle East 1
Table 3.5 Competitiveness of Middle Eastern pharmaceutical markets
Table 3.6 Pharmaceutical imports and exports in the Middle East, 2003
Table 4.1 Egypt's healthcare spending
Table 4.2 Egypt's health and government budgets
Table 4.3 Consumer expenditure on health goods and medical services (LEm)
Table 4.4 OTC sales (LEm)
Table 4.5 Egypt's average annual patient co-payment (Egyptian pounds)
Table 4.6 Egypt's top 10 pharmaceutical companies, by revenue, 2001
Table 4.7 Egypt's top 10 pharmaceutical products, by revenue, 2001
Table 4.8 PEST factors affecting Egypt's pharmaceutical industry
Table 5.1 Israel's healthcare expenditure
Table 5.2 Israel's pharmaceutical market, at retail prices
Table 5.3 Israel's consumer expenditure on health goods and medical services
Table 5.4 Israel's pharmaceutical exports and imports
Table 5.5 Israel's non-prescription pharmaceutical market, at retail prices
Table 5.6 Retail sales of OTC healthcare in Israel
Table 5.7 Co-payments for medicines by sick fund in Israel
Table 5.8 Teva's sales and net income
Table 5.9 PEST factors affecting Israel's pharmaceutical industry
Table 6.1 Jordan's health insurance coverage
Table 6.2 Breakdown of Jordan's public health spending
Table 6.3 Jordan's Ministry of Health budgets, 2000-04 (JDm)
Table 6.4 Jordan's health insurance budget, 2000-02 (JDm)
Table 6.5 Admission costs for Jordan's public hospitals
Table 6.6 Dar Al Dawa financials
Table 6.7 PEST factors affecting Jordan's pharmaceutical industry
Table 7.1 Lebanon's pharmaceutical market size and imports
Table 7.2 Co-payments by insurer, in Lebanon
Table 7.3 Hospital co-payments by insurer, in Lebanon
Table 7.4 Lebanon's pharmaceutical production and exports
Table 7.5 PEST factors affecting Lebanon's pharmaceutical industry
Table 8.1 Saudi health-sector statistics, 2003
Table 8.2 Saudi healthcare spending
Table 8.3 Saudi consumer expenditure on health goods and services
Table 8.4 The Saudi private pharmaceutical market
Table 8.5 Saudi pharmaceutical imports (SRm)
Table 8.6 Saudi retail sales of OTC healthcare
Table 8.7 SPIMACO sales and profits, 2003 and 2004
Table 8.8 Tabuk's turnover
Table 8.9 Market share estimates for the Saudi private market, 2005
Table 8.10 Sales estimates for leading products in the Saudi private market, 2005
Table 8.11 Estimates of leading products by units in the Saudi private market, 2005
Table 8.12 PEST factors affecting the Saudi pharmaceutical industry
Table 9.1 Dubai's trade in pharmaceutical products
Table 9.2 Revenue of Drug Control Department by category (in AED)
Table 9.3 Julphar sales and profits
Table 9.4 PEST factors affecting the pharmaceutical industry in the UAE